Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $1.5 million.

  • C4 Therapeutics' Depreciation and Depletion rose 5.21% to $384,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 31.27%. This contributed to the annual value of $1.5 million for FY2024, which is 6.65% down from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Depreciation and Depletion is $1.5 million, which was down 6.65% from $1.6 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Depreciation and Depletion peaked at $1.7 million during FY2022, and registered a low of $1.5 million during FY2024.
  • Moreover, its 3-year median value for Depreciation and Depletion was $1.6 million (2023), whereas its average is $1.6 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first dropped by 7.73% in 2021, then grew by 12.33% in 2022.
  • Over the past 5 years, C4 Therapeutics' Depreciation and Depletion (Yearly) stood at $1.6 million in 2020, then fell by 7.73% to $1.5 million in 2021, then increased by 12.33% to $1.7 million in 2022, then declined by 5.85% to $1.6 million in 2023, then declined by 6.65% to $1.5 million in 2024.